Health Care Facilities

Sanbo

Sanbo released FY2026 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 445.19 M, actual EPS CNY 0.07

Sanbo to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

Sanbo released FY2025 Q4 earnings on April 21 After-Market (BJT), actual revenue CNY 451.88 M, actual EPS CNY 0.0026

Sanbo released FY2025 Annual Earnings on April 21 After-Market (BJT), Actual Revenue: CNY 1.725 B, Actual EPS: CNY 0.41

Sanbo to Release FY2025 Earnings on April 22 After-Market (BJT)

Sanbo released FY2025 Q3 earnings during market hours on October 27 (BJT), with actual revenue of CNY 445.99 M and EPS of CNY 0.0689

Sanbo released FY2025 9 Months Earnings on October 27 During-Market BJT, actual revenue CNY 1.273 B, actual EPS CNY 0.4096

Sanbo FY2025 Q3 Earnings Release on October 28, 2025 During-Market (BJT)

Sanbo released FY2025 Q2 earnings on August 26 After-Market (BJT), actual revenue CNY 433.78M, actual EPS CNY 0.1506

Sanbo released FY2025 Semi-Annual earnings on August 26 After-Market (BJT), actual revenue CNY 827.25 M, actual EPS CNY 0.34

Sanbo FY2025 Semi-Annual Earnings Release on August 27, 2025 (BJT)

Sinbo Neurology Completes Intracranial Brain-Computer Interface Trial

Three 博 Brain Science Introduces Brain-Computer Interface Technology in Treating Movement Disorders

TBP Implements Share Reduction Plan for Sanbo Neurology

Siben Neuro Expanding Business Through Mergers and Acquisitions

Sibor Neurology ESG Rating Upgraded to B

Significant Progress in Brain-Computer Interface Research by Sibo Neurology and Partners

Three 博 Brain Sci 董秘回应投资者问题

Sinoboom Neurology Discussing Cooperation with Brain Tech Companies

Concluded Share Repurchase Completed by Sanbo Brain Science

516500

003008

159898

159883

562600

159837

159849

516930

301293

Tao Hu, founder of BrainCo, stated that China's gap with international counterparts in core brain-computer interface technology is rapidly narrowing. Leveraging advantages in clinical applications and policy, China is expected to achieve large-scale implementation in the medical sector. He pointed out that the gap between China and the US in invasive brain-computer interface technology is not significant, mainly differing in details, and this gap is shrinking quickly

Wallstreetcn

ChinaAMC CSI Biotechnology Theme ETF

KETOP

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

BrainCo's Tao Hu: Breaking Through with Flexible Brain-Computer Interfaces, Aligning Chinese Technology with Global Implementation

The Jiangsu Provincial Department of Industry and Information Technology and nine other departments issued the "Action Plan for the Innovative Development of the Brain-Computer Interface Industry in Jiangsu Province," emphasizing the integration and adaptation of core hardware and software systems such as brain-computer interface sensors, chips, and batteries, promoting the development of products towards intelligence, lightweight, high speed, and low power consumption. The plan aims to develop related equipment in the industrial, medical, and consumer sectors, and to recognize no less than 30 brain-computer interface products by 2030

Jiangsu: Strengthen the integration and adaptation of core hardware and software systems such as brain-machine interface sensors, chips, and batteries

688767

300753

688626

The A-share brain-computer interface concept is actively defying the trend, with BIOTEST BIOTECH rising over 10%, and Meihao Medical, Sanbo, APON, and Xiangyu Medical following suit

BIOTEST BIOTECH

APON

Xiangyu Medical

BrainTiger Technology announced that its first clinical patient with a fully functional brain-computer interface can independently complete the purchase of New Year goods, write auspicious characters, and send red envelopes. The company's newly developed XessKey component changes the traditional usage model of brain-computer interfaces, allowing patients to connect and control devices such as tablets and computers just like using ordinary electronic products

36Kr

Brain Tiger Technology: The first "Three Full" clinical patient can now independently complete the preparation of New Year goods, write the character for good fortune, and send red envelopes

Sanbo Neuroscience released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 1.273 billion yuan, a year-on-year increase of 20.26%. The net profit attributable to the parent company was 83.6282 million yuan, a year-on-year decrease of 20.01%; the net profit after deducting non-recurring gains and losses was 84.9638 million yuan, a year-on-year decrease of 4.85%. The basic earnings per share were 0.41 yuan

Zhitong

Sanbo Neuroscience released its performance for the first three quarters, with a net profit attributable to the parent company of 83.6282 million yuan, a decrease of 20.01%

On September 24th, Sanbo stated on the interactive platform that the company's brain-computer interface is still in the experimental development and laboratory validation stage, and there is still a series of validation processes before it can be maturely applied. Currently, it will not have a significant impact on the company

Sanbo: The company's brain-computer interface is still in the experimental development and laboratory validation stage

Sanbo announced that it will participate as a limited partner in the establishment of Tianjin Yuanming Haihe Brain Science Venture Capital Partnership, planning to raise funds of 300 million yuan, with the company subscribing 57 million yuan of its own funds. This move aims to improve the industrial chain, enhance clinical diagnosis and treatment levels, and focus on investments in the field of brain science, particularly in the areas of brain disease examination, treatment, and health management, to strengthen the company's competitiveness

Sanbo Neuroscience plans to participate in the investment to establish Tianjin Yuanming Haihe Brain Science Venture Capital Partnership

601718

002195

002173

Brain-computer interface concept stocks fell at the beginning of trading, Innovative Medical hit the limit down, Stonehill Technology dropped over 7%, Aiteng Medical, Sanbo, and Jihua Group all declined

Jihua Group

Stonehill Technology

Innovative Medical

Brain-computer interface concept stocks fell at the beginning of trading, Innovative Medical hit the limit down

Sanbo(301293.SZ)